|25 NOV 2014|
|Thomson Reuters to Highlight its Legal Business at the RBC Capital Markets Telecommunications, Media & Technology Deep Dive Conference|
|NEW YORK – Susan Taylor Martin, president of the Legal business of Thomson Reuters (TSX/NYSE: TRI), will present at the RBC Capital Markets Telecommunications, Media & Technology Deep Dive Conference on Thursday, December 4, 2014. The presentation may include forward looking information.
An audio recording will be made available in the “Investor Relations” section of the Thomson Reuters website following the conclusion of the conference.
Thomson Reuters is the world's ... |
|04 NOV 2014|
|Thomson Reuters Announces Pricing of C$550 Million Note Offering|
|NEW YORK – Thomson Reuters (TSX / NYSE: TRI) today announced the pricing of its offering of C$550 million (approximately US$483 million) principal amount of 3.309% notes due 2021. The offering is expected to close on November 12, 2014, subject to customary closing conditions. Thomson Reuters plans to use the net proceeds of this offering for general corporate purposes, including, without limitation, to fund the redemption of all of its outstanding C$750 million principal amount of 6.00% notes du... |
|04 NOV 2014|
|Thomson Reuters to Redeem C$750 Million of Debt Securities|
|NEW YORK – Thomson Reuters (TSX / NYSE: TRI) today announced it will exercise its right to redeem all of its C$750 million principal amount of 6.00% notes due March 31, 2016 (CUSIP No. 884903 BE4). Thomson Reuters plans to finance the redemption through the issuance of new debt securities.
The redemption price will include an early repayment premium as well as accrued and unpaid interest through the redemption date (which is expected to be on or about December 4, 2014). When available, Thomson... |
Hard copies of Thomson Reuters audited financial statements are available free of charge upon request. Our financial statements are also available online within our latest annual report to shareholders and are also included in our annual report on Form 40-F.